Clinical Trials Logo

Pulmonary Emphysema clinical trials

View clinical trials related to Pulmonary Emphysema.

Filter by:

NCT ID: NCT01041586 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

Bronchoscopic Thermal Vapor Ablation (BTVA) for Lung Volume Reduction

BTVA
Start date: December 2009
Phase: Phase 1
Study type: Interventional

To assess the safety and efficacy of BTVA for the treatment of patients with heterogeneous upper lobe emphysema.

NCT ID: NCT00995852 Recruiting - Pulmonary Emphysema Clinical Trials

Unilateral Versus Bilateral Endoscopic Lung Volume Reduction A Comparative Case Study

Start date: September 2009
Phase: Phase 2/Phase 3
Study type: Interventional

Patients with bilateral heterogeneous pulmonary emphysema benefit to differing degrees from unilateral ELVR with complete lobe closure in comparison with incomplete bilateral treatment.

NCT ID: NCT00974064 Completed - Smoking Cessation Clinical Trials

The Natural History of Gene Expression in the Lung Cells of Non-Smokers, Smokers and Ex-Smokers in Health and Disease

Start date: August 2009
Phase:
Study type: Observational

Cigarette smoking is the major risk factor for chronic obstructive pulmonary disease (COPD, commonly known as chronic bronchitis and emphysema). Despite this clear link, only 15-20% of smokers develop COPD suggesting that genetic factors affect the lung's susceptibility to the stress of cigarette smoke. The cells lining the airways (epithelium) and cells that help defend the lung (alveolar macrophages) of smokers develop gene expression changes that are different from that of nonsmokers. In the investigators' previous studies they have demonstrated that there are greater than 200 genes that are responsive to cigarette smoke in these cells. But the investigators do not know whether the gene expression is static or changes as a function of time. Genes that show significant changes over time may be relevant to the progression of the disease. Even though quitting smoking reduces the rate at which the lungs decline, many-smokers still go on to develop COPD. This study will provide insights into the natural history of smoking-related gene expression of the lung cells in health and disease.

NCT ID: NCT00884962 Completed - Advanced Emphysema Clinical Trials

A Dose Ranging Study of the Aeris Polymeric Lung Volume Reduction (PLVR) System in Patients With Advanced Upper Lobe Predominant Emphysema

Start date: December 2008
Phase: Phase 1
Study type: Interventional

This is a multi-center, open-label, non-controlled Pilot Study. Approximately 24 patients will be assigned to one of 3 treatment groups (8 patients each group). Patients in each group will receive 2, 4, and 6 (3 followed by a retreatment of 3) subsegmental treatments, respectively. All patients will receive treatment in a single lung under conscious sedation or general anesthesia. Patients will be followed for 24 weeks after completion of PLVR treatment(s). Upon completion of 12-week follow-up, all safety and efficacy data will be analyzed to determine an effective treatment dose. Thereafter, Group 1 patients may elect to be retreated at additional sites so that their total dose received is consistent with the effective dose. All study patients will receive standard medical therapy in addition to PLVR.

NCT ID: NCT00869544 Completed - HIV Infections Clinical Trials

Pneumocystis in Pathogenesis of HIV-associated Emphysema

PACT
Start date: August 2007
Phase:
Study type: Observational

A. Statement of Hypotheses: HIV-infected patients have an increased incidence of emphysema compared to non-HIV-infected smokers, and it has been hypothesized that this accelerated disease progression is the result of one or more latent infections that amplifies the pulmonary inflammatory response to cigarette smoke. Pneumocystis is one infectious agent that likely plays a key role in the development of HIV-associated emphysema. Colonization with Pneumocystis has been demonstrated in HIV-infected subjects, and HIV-infected smokers are particularly susceptible to Pc colonization regardless of CD4 cell count or use of prophylaxis. Pneumocystis colonization is also increased in non-HIV-infected patients with chronic obstructive pulmonary disease (COPD) and is directly related to the severity of the disease. The presence of Pneumocystis in the lungs, even at low levels as seen in colonization, produces inflammatory changes similar to those seen in COPD, with increases in the numbers of neutrophils and cytotoxic CD8+ lymphocytes. We propose that Pneumocystis accelerates emphysema in HIV-infected smokers by stimulating inflammation and tissue destruction. We will examine the role of co-infection with Pneumocystis in the pathogenesis of HIV-associated emphysema and the mechanism by which it causes emphysema progression. These studies will lead to information that will provide a rational basis for prevention and therapy of HIV-associated emphysema and provide a model for emphysema in the general population

NCT ID: NCT00857038 Not yet recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

Doxycycline and Airway Inflammation in Chronic Obstructive Pulmonary Disease (COPD)

Start date: April 2009
Phase: Phase 4
Study type: Interventional

COPD is a progressive pulmonary disease that is characterized by an inflammatory process in the airways and the lungs which leads to progressive airway obstruction. The inflammation is associated with tissue loss and remodelling. The investigators hypothesized that doxycycline reduces neutrophilic airway inflammation in patients with COPD. Therefore the investigators will conduct a randomized trial of doxycycline in 30 patients.

NCT ID: NCT00825578 Completed - Clinical trials for Heterogeneous Emphysema

Use of Endobronchial Valves in Non-Upper Lobe Heterogeneous Emphysema

Start date: January 2009
Phase: Phase 3
Study type: Interventional

Hypothesis: Patients with advanced emphysema with predominance of the disease in areas other than the upper lobes, as determined by high resolution computed tomography (HRCT), could have a positive response to valve treatment.

NCT ID: NCT00823927 Completed - HIV Infections Clinical Trials

Alveolar Macrophage Proteomics in HIV-associated Emphysema

HIVE
Start date: April 21, 2006
Phase:
Study type: Observational

This study is being done to examine lung function changes in individuals with HIV infection and to understand why individuals with HIV have increased risk of lung damage from cigarette smoking.

NCT ID: NCT00757120 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Biomarkers and Genetic Factors Related to Emphysema

Start date: October 2007
Phase:
Study type: Observational

Emphysema, a common type of chronic obstructive pulmonary disease (COPD), is a long-term lung disease that is usually caused by cigarette smoking. This study will examine both current smokers and former smokers who have emphysema, as well as current and former smokers who do not have emphysema, to determine if certain factors found in the blood are related to the risk of developing emphysema.

NCT ID: NCT00730301 Unknown status - Clinical trials for Chronic Obstructive Pulmonary Disease

EUROPT Clinical Trial to Study the Efficacy of One-Way Valve Implantation (New Treatment Algorithm) in Patients With Heterogeneous Emphysema

EUROPT
Start date: July 2007
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess the efficacy of a new treatment algorithm for bronchoscopic lung volume reduction (BLVR) in patients with emphysema based on the information of emphysema heterogeneity, destruction score, and fissure analysis.